Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

4c7083b3-eccc-4d80-a31d-6fd3cd0222b4

—

4e7ce202-9fd6-5616-93f5-1ff40ab62dd2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
age_years
60

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
  • ANGIOGENESIS+0.480
  • TGF_BETA_SIGNALING+0.470
  • COAGULATION+0.420
  • UV_RESPONSE_DN+0.420
  • ESTROGEN_RESPONSE_EARLY+0.390
  • PANCREAS_BETA_CELLS+0.390
  • APICAL_JUNCTION+0.360
  • HYPOXIA+0.360
  • APICAL_SURFACE+0.350

Top 10 suppressed

  • E2F_TARGETS-0.670
  • MYC_TARGETS_V2-0.640
  • G2M_CHECKPOINT-0.580
  • MYC_TARGETS_V1-0.560
  • DNA_REPAIR-0.440
  • MTORC1_SIGNALING-0.410
  • OXIDATIVE_PHOSPHORYLATION-0.400
  • UNFOLDED_PROTEIN_RESPONSE-0.390
  • PI3K_AKT_MTOR_SIGNALING-0.270
  • INTERFERON_ALPHA_RESPONSE-0.230

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-75-7030-01A-11R-1949-07
lung-landscapes@6
—cohortA10.937
2TCGA-E2-A153-01A-12R-A12D-07
breast-umap@18
—A0.935
3TCGA-BH-A0AZ-01A-21R-A12P-07
breast-umap@18
—A0.934
4TCGA-BH-A0DV-01A-21R-A12P-07
breast-umap@18
—A0.933
5TCGA-K4-A4AB-01B-12R-A28M-07
bladder-landscape@3
——0.928
6ULC1729T_S65
lung-landscapes@6
—cohortSQ10.918
7TCGA-A2-A0ES-01A-11R-A115-07
breast-umap@18
—A0.917
8TCGA-BH-A0DP-01A-21R-A056-07
breast-umap@18
—A0.910
9TCGA-A2-A0EO-01A-11R-A034-07
breast-umap@18
—A0.908
1020030015.LumB
breast-umap@18
—A0.905

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.550Inavolisib— uncovered
ANGIOGENESIS0.480Remibrutinib— uncovered
TGF_BETA_SIGNALING0.470Inavolisib— uncovered
COAGULATION0.420Binimetinib— uncovered
UV_RESPONSE_DN0.420Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.390Inavolisib— uncovered
PANCREAS_BETA_CELLS0.390Cobimetinib— uncovered
APICAL_JUNCTION0.360Inavolisib— uncovered
HYPOXIA0.360Idelalisib— uncovered
APICAL_SURFACE0.350Temsirolimus— uncovered
MYOGENESIS0.350Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.350Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.330Idelalisib— uncovered
ANDROGEN_RESPONSE0.310Inavolisib— uncovered
HEDGEHOG_SIGNALING0.310Inavolisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
KRAS_SIGNALING_UP0.290Inavolisib— uncovered
APOPTOSIS0.280Idelalisib— uncovered
KRAS_SIGNALING_DN0.260Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.240Idelalisib— uncovered